Artificial Intelligence Can Predict Cancer Survival Using Data From a Single Consultation
Artificial intelligence can predict survival in cancer patients using information from a patient’s initial consultation with an oncologist, a study suggests.
All articles by Laura Healy
Responses Fleeting With CAR-T Reinfusion in Children, AYAs With B-ALL
Reinfusion with the CAR T-cell therapy tisagenlecleucel does not produce durable remissions in children and AYAs with B-ALL, a study suggests.
Treatment for Relapsed SCLC Remains “Area of High Unmet Need”
Researchers found a lack of promising investigational treatments in late-stage development for SCLC in the second-line setting and beyond.
Zamtocabtagene Autoleucel Produces High ORR in Relapsed/Refractory DLBCL
Zamtocabtagene autoleucel produced responses in patients with relapsed/refractory diffuse large B-cell lymphoma in a phase 2 trial.
“Severe4” Predicts Outcomes of CAR T-Cell Therapy in Relapsed/Refractory DLBCL
A prognostic index called “Severe4” can predict outcomes of CAR T-cell therapy in patients with relapsed/refractory DLBCL, a study suggests.
Second-Line Bevacizumab Provides No Benefit in Advanced Neuroendocrine Carcinoma
Adding bevacizumab to second-line chemotherapy does not improve survival in patients with advanced neuroendocrine carcinoma, a phase 2 study suggests.
- Loading...
Loading...
Next post in General Oncology
Loading... 
Loading...